Smoking Cessation and Nicotine De

Smoking Cessation and Nicotine De-Addiction Market to Reach US$ 13,657.6 Mn by 2026
According to a new market report published by Transparency Market Research titled ‘Smoking
Cessation and Nicotine De-Addiction Market [(Products (with Nicotine) - (OTC Products and
Prescription Products); (OTC Products - E-cigarettes, Nicotine Gums (NRT), Nicotine Patches
(NRT), Nicotine Lozenges (NRT) and Nicotine Tablets (NRT)); (Prescription Products - Nicotine
Sprays (NRT) and Nicotine Inhalers (NRT))]; [Products (without Nicotine) – (Prescription
Products - Zyban and Chantix)] – Global Industry Analysis, Size, Share, Growth, Trends, and
Forecast, 2018 – 2026, the global smoking cessation and nicotine de-addiction market is expected to
reach US$ 13,657.6 Mn by 2026, expanding at a CAGR of 4.5% from 2018 to 2026. The market is
segmented by regions into North America, Europe, Asia Pacific, Middle East & Africa (MEA), and South
America.
The North America smoking cessation and nicotine de-addiction market is the largest in the world. In
North America, nicotine containing smoking cessation products hold a major market share. In North
America, OTC smoking cessation and nicotine de-addiction products hold a significant share of the
market compared to nicotine containing prescription smoking cessation products. E-cigarette is the most
dominant type of nicotine containing OTC smoking cessation product in North America. The U.S. is the
largest smoking cessation and nicotine de-addiction market in North America and the world. Canada is
the second largest smoking cessation market in North America. The smoking cessation and nicotine deaddiction market in Europe is the second largest in the world.
Request A Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1849
In the Europe smoking cessation and nicotine de-addiction market, nicotine containing OTC products
hold a prominent share compared to nicotine containing prescription products. Nicotine containing OTC
products such as e-cigarettes, nicotine gum, nicotine transdermal patches, nicotine lozenges, and nicotine
tablets are most popular among European consumers. The number of e-cigarette consumers is increasing
in major European countries. EU e-cigarette regulations apply to EU countries and are not applicable in
the U.K. after Brexit. The U.K. is the second largest smoking cessation and nicotine de-addiction market
in the world after the U.S. and the largest market in Europe. France and Germany are the second and third
largest smoking cessation markets in Europe.
The Asia Pacific smoking cessation and nicotine de-addiction market is the third largest market in the
world. In the Asia Pacific smoking cessation and nicotine de-addiction market, nicotine containing OTC
products hold a dominant share compared to nicotine containing prescription products. Nicotine
containing OTC products such as e-cigarettes, nicotine gum, nicotine transdermal patches, nicotine
lozenges, and nicotine tablets are increasing their penetration in the Asia Pacific region. China is the
largest smoking cessation and nicotine de-addiction market in Asia Pacific. Japan and India are the
second and third largest smoking cessation markets in the region.
Download Report TOC for in-depth analysis @ https://www.transparencymarketresearch.com/reporttoc/1849
In MEA, it is estimated that 180 million men are expected to be smokers by 2025 which is 2X the number
of smokers in the region in the year 2000. In 2002, the tobacco market in MEA was worth US$ 15.3
billion which increased to US$ 28.7 billion in 2009 and is expected to reach US$ 50.0 billion in 2020. As
tobacco consumption is increasing in MEA, ill effects of tobacco are bound to increase, which is expected
to drive the demand for smoking cessation and nicotine de-addiction products in the region.
The report highlights major companies operating in the global smoking cessation and nicotine deaddiction market including Pfizer Inc., GlaxoSmithKline plc (GSK), Cipla Ltd., Johnson & Johnson
(J&J), ITC Ltd., Takeda Pharmaceutical Company Ltd., Alkalon A/S, 22nd Century Group, Inc., Strides
Pharma Science Ltd., and JUUL Labs, Inc.

Download Report